- Home
- NWN vs TVTX Comparison
NWN vs TVTX Comparison
Compare NWN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWN
- TVTX
- Stock Information
- Founded
- NWN 1859
- TVTX 2008
- Country
- NWN United States
- TVTX United States
- Employees
- NWN N/A
- TVTX N/A
- Industry
- NWN Oil/Gas Transmission
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- NWN Utilities
- TVTX Health Care
- Exchange
- NWN Nasdaq
- TVTX Nasdaq
- Market Cap
- NWN 1.5B
- TVTX 1.3B
- IPO Year
- NWN N/A
- TVTX N/A
- Fundamental
- Price
- NWN $41.14
- TVTX $17.72
- Analyst Decision
- NWN Strong Buy
- TVTX Buy
- Analyst Count
- NWN 2
- TVTX 13
- Target Price
- NWN $43.50
- TVTX $23.46
- AVG Volume (30 Days)
- NWN 228.6K
- TVTX 1.4M
- Earning Date
- NWN 11-12-2024
- TVTX 10-31-2024
- Dividend Yield
- NWN 4.76%
- TVTX N/A
- EPS Growth
- NWN N/A
- TVTX N/A
- EPS
- NWN 2.06
- TVTX N/A
- Revenue
- NWN $1,137,832,000.00
- TVTX $203,447,000.00
- Revenue This Year
- NWN N/A
- TVTX $62.45
- Revenue Next Year
- NWN $3.62
- TVTX $59.30
- P/E Ratio
- NWN $19.98
- TVTX N/A
- Revenue Growth
- NWN N/A
- TVTX 57.08
- 52 Week Low
- NWN $34.82
- TVTX $5.12
- 52 Week High
- NWN $42.56
- TVTX $20.33
- Technical
- Relative Strength Index (RSI)
- NWN 56.55
- TVTX 51.53
- Support Level
- NWN $40.38
- TVTX $16.89
- Resistance Level
- NWN $42.56
- TVTX $19.51
- Average True Range (ATR)
- NWN 0.92
- TVTX 1.23
- MACD
- NWN 0.14
- TVTX -0.16
- Stochastic Oscillator
- NWN 68.65
- TVTX 26.69
About NWN Northwest Natural Holding Company
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.